Dallas, Texsa (PRWEB) February 17, 2015
The research estimates that the market for generic drugs will account for nearly $350 Billion in revenue by the end of 2015. Despite challenges relating to quality control and legal concerns, the market is poised for significant growth in the coming years. Increased initiatives by government and healthcare service providers are one of the major trends emerging in the market. Doctors and pharmacists are encouraged to use generics and reassure patients of their quality and efficacy. The generic drugs market is expected to grow at a CAGR of 12% between 2015 and 2020, driven by growth in both established and developing markets.
The generic drugs are now finding their way into markets such as Japan. According to another report, “Generic Drugs Market in Japan 2015-2019,” the market in Japan is forecast to grow at a CAGR of 8.16 percent over the period 2014-2019. According to the report, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, leading to competition from generic drugs. As a result of the economic crisis, the development of new drugs has been hindered. Major companies in the market have allocated minimal funds for the R&D of innovative drugs. This has led to the drying up of pipeline drugs, paving the way for the Generic Drugs market.
The report comes with an associated Excel datasheet suite covering quantitative data from all numeric forecasts presented in the report.
List of Companies Mentioned: Abbott Laboratories, AbbVie, ACETO Corporation, Acino Holding, Actavis, Actelion, Adcock Ingram, Aesica Pharmaceuticals, Ajinomoto, Akron, Alexion Pharmaceuticals, Alfa Wasserman, Allergan, Almirall, AMA (African Medicines Regulatory Agency), Amgen, Amneal Pharmaceuticals, AMRI (Albany Molecular Research, Inc.), ApoPharma , Apotex, Arch Pharmalabs, ASKA Pharmaceutical Company, Aspen Holdings, Astellas Pharma, AstraZeneca, Aurobindo Pharma, Auxilium Pharmaceuticals, Baxter BioScience, Baxter International , Bayer AG, BD (Becton, Dickinson and Company), BD Rx, Berlin Chemie, Biocon, Biogaran, Biogen Idec, Biogen Laboratorios, BMS (Bristol-Myers Squibb), Boehringer Ingelheim, Boots UK, BPI (Breckenridge Pharmaceutical Inc.), Breckenridge Pharmaceutical , Cadila Healthcare (Zydus Cadila), Cadila Pharmaceuticals, CBER (Centre for Biologics Evaluation and Research), CDER (Centre for Drug Evaluation and Research) , CDSCO (Central Drug Standards and Control Organization, India), Cedarburg Pharmaceuticals, Celgene Corporation, Celltrion Group, CFDA (China Food and Drug Administration), Chiesi Farmaceutici, Chugai Pharmaceutical Company, Cipla, Claris Injectables, Claris Lifesciences, Claris Otsuka, Coherus BioSciences, Consort Medical, Covidien, Cubist Pharmaceuticals, Cypress Pharmaceutical, Daiichi Sankyo, Daiichi Sankyo Espha and Company and more.
Order a copy of this report at (Prices start at US $ 2500 for a single user PDF) http://www.reportsnreports.com/purchase.aspx?name=344436.
Historical Revenue & Forecast Segmentation:
Generic drugs market forecasts are provided for each of the following submarkets and their subcategories:
- Brand Classification
o Pure (Non-branded) Generics
o Branded Generics
o Super Generics
- Therapeutic Area
o Cardiovascular & Hypertension
o CNS (Central Nervous System)
o Hormonal Drugs
o Pain Relief
- Regional Markets
- Country Markets
Explore other new reports by Signals and Systems Telecom Market at http://www.reportsnreports.com/publisher/signals-and-systems-telecom/.
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email, the details on sales at reportsandreports.com.